المؤلفون: V. V. Salukhov, E. A. Kovalevskaya, Т. A. Ilyinskaya, В. В. Салухов, Е. А. Ковалевская, T. А. Ильинская

المصدر: Meditsinskiy sovet = Medical Council; № 6 (2024); 24-35 ; Медицинский Совет; № 6 (2024); 24-35 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: липиды, DPP-4 inhibitors, cardiovascular outcomes, atherosclerosis, lipids, ингибиторы ДПП-4, сердечно-сосудистые исходы, атеросклероз

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8267/7290; Богданова ЕА, Шустов СБ, Свистов АС, Кицышин ВП. Особенности ишемии миокарда у больных сахарным диабетом 2-го типа в сочетании с ишемической болезнью сердца по данным суточного мониторирования электрокардиограммы. Вестник Российской Военно-медицинской академии. 2012;(1):44. Режим доступа: https://www.vmeda.org/wp-content/uploads/2016/pdf/44-48.pdf.; Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. https://doi.org/10.1016/j.diabres.2019.107843.; Дедов ИИ, Шестакова МВ (ред.). Осложнение сахарного диабета: лечение и профилактика. М.: МИА; 2017.; Дедов ИИ, Шестакова МВ, Майоров АЮ, Мокрышева НГ, Андреева ЕН, Безлепкина ОБ и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023;26(2S):1–157. https://doi.org/10.14341/DM13042.; Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022–2031. https://doi.org/10.1161/circulationaha.118.038868.; Nesti L, Natali A. Metformin efects on the heart and the cardiovascular system: a review of experimental and clinical data. Nutr Metab Cardiovasc Dis. 2017;27(8):657–669. https://doi.org/10.1016/j.numecd.2017.04.009.; Салухов ВВ, Халимов ЮШ, Шустов СБ, Кадин ДВ. Снижение кардиоваскулярного риска у пациентов с сахарным диабетом 2-го типа: обзор основных стратегий и клинических исследований. Сахарный диабет. 2018;21(3):193–205. https://doi.org/10.14341/DM9570.; DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links: the Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270–1287. https://doi.org/10.1007/s00125-010-1684-1.; Nesti L, Tricò D, Mengozzi A, Natali A. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol. 2021;20(1):109. https://doi.org/10.1186/s12933-021-01294-7.; Пешева ЕД, Фадеев ВВ. Пиоглитазон – забытый сахароснижающий препарат с доказанными кардиопротективными и нефропротективными свойствами. Consilium Medicum. 2021;23(4):366–371. Режим доступа: https://consilium.orscience.ru/2075-1753/article/download/95453/PDF.; Djouadi F, Lecarpentier Y, Hébert JL, Charron P, Bastin J, Coirault C. A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc Res. 2009;84(1):83–90. https://doi.org/10.1093/cvr/cvp183.; Салухов ВB, Ковалевская ЕА. Переосмысление роли пиоглитазона в современной диабетологии с позиции его кардиоренопротективных свойств. Медицинский совет. 2022;16(10):10–21. https://doi.org/10.21518/2079-701X-2022-16-10-10-21.; Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–1573. https://doi.org/10.1001/jama.299.13.1561.; Салухов ВВ, Котова МЕ. Основные эффекты, вызываемые ингибиторами SGLT2 у больных сахарным диабетом типа 2, и механизмы, которые их определяют. Эндокринология: новости, мнения, обучение. 2019;8(3):61–74. https://doi.org/10.24411/2304-9529-2019-13007.; DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(2):157–163. https://doi.org/10.2337/dc09-S302.; DeFronzo RA, Ferrannini E, Groop L. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1:15019. https://doi.org/10.1038/nrdp.2015.19.; Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305–315. https://doi.org/10.7326/m15-1774.; Салухов ВВ, Ильинская ТА, Минаков АА. Влияние современной сахароснижающей терапии на массу тела у больных сахарным диабетом 2-го типа. Эндокринология: новости, мнения, обучение. 2022;11(1):39–52. https://doi.org/10.33029/2304-9529-2022-11-1-39-52.; Clarke GD, Solis-Herrera C, Molina-Wilkins M, Martinez S, Merovci A, Cersosimo E et al. Pioglitazone improves left ventricular diastolic function in subjects with diabetes. Diabetes Care. 2017;40(11):1530–1536. https://doi.org/10.2337/dc17-0078.; Вербовой АФ, Вербовая НИ, Долгих ЮА. Симбиоз кардиологии и эндокринологии. Медицинский совет. 2020;(14):80–89. https://doi.org/10.21518/2079-701X-2020-14-80-89.; Ильинская ТА, Кицышин ВП, Салухов ВВ. Влияние нарушения регуляции углеводного обмена на циркадную вариабельность гликемии и ее роль в развитии кардиоваскулярных осложнений у больных сахарным диабетом 2-го типа. Фарматека. 2021;(4):84–89. https://doi.org/10.18565/pharmateca.2021.4.84-89.; Кицышин ВП, Салухов ВВ, Демидова ТА, Сардинов РТ. Циркадная модель регуляции углеводного обмена в норме. Consilium Medicum. 2016;18(4):38–42. Режим доступа: https://consilium.orscience.ru/2075-1753/article/view/94447.; Song J, Walsh MF, Igwe R, Ram JL, Barazi M, Dominguez LJ, Sowers JR. Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes. 1997;46(4):659–664. https://doi.org/10.2337/diab.46.4.659.; Gale EA. Lessons from the glitazones: a story of drug development. Lancet. 2001;357(9271):1870–1875. https://doi.org/10.1016/s0140-6736(00)04960-6.; Lebovitz HE. Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep. 2019;19(12):151. https://doi.org/10.1007/s11892-019-1270-y.; Yang T. Kidney-specifc gene targeting: insight into thiazolidinedioneinduced fuid retention. Nephrology. 2006;11(3):201–206. https://doi.org/10.1111/j.1440-1797.2006.00566.x.; Saad S, Agapiou DJ, Chen XM, Stevens V, Pollock CA. The role of Sgk-1 in the upregulation of transport proteins by PPAR-{gamma} agonists in human proximal tubule cells. Nephrol Dial Transplant. 2009;24(4):1130–1141. https://doi.org/10.1093/ndt/gfn614.; Шестакова МВ, Анциферов МБ, Аметов АС, Галстян ГР, Демидова ТЮ, Мкртумян АМ, Петунина НА. Возможности применения фиксированной комбинации алоглиптина и пиоглитазона в условиях современной парадигмы лечения сахарного диабета 2-го типа. Сахарный диабет. 2021;24(2):193–197. https://doi.org/10.14341/DM12757.; de Jong M, van der Worp HB, van der Graaf Y, Visseren FLJ, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol. 2017;16(1):134. https://doi.org/10.1186/s12933-017-0617-4.; Asakura M, Kim J, Asanuma H, Nakama Y, Tsukahara K, Higashino Y et al. Cardiovascular outcomes in patients with previous myocardial infarction and mild diabetes mellitus following treatment with pioglitazone: reports of a randomised trial from The Japan Working Group for the Assessment Whether Pioglitazone Protects DM Patients Against Re-Infarction (PPAR study). EClinicalMedicine. 2018;4-5:10–24. https://doi.org/10.1016/j.eclinm.2018.09.006.; Doehner W, Erdmann E, Cairns R, Clark AL, Dormandy JA, Ferrannini E, Anker SD. Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol. 2012;162(1):20–26. https://doi.org/10.1016/j.ijcard.2011.09.039.; Демидова ТЮ, Кочина АС. Алоглиптин и пиоглитазон. Перспективы комбинированного примененияю. Эндокринология: новости, мнения, обучение. 2021;10(4):62–68. https://doi.org/10.33029/2304-9529-2021-10-4-62-68.; Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(1):111–134. https://doi.org/10.2337/dc20-S010.; Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T et al. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientifc statement from the American Heart Association. Circulation. 2016;134(23):e535–e578. https://doi.org/10.1161/CIR.0000000000000450.; Демидова ИЮ, Горохова ТВ. Эффективность применения пиглитазона в лечении больных сахарным диабетом 2 типа. Эффективная фармакотерапия. 2009;(3):26–31. Режим доступа: https://umedp.ru/articles/effektivnost_primeneniya_pioglitazona_v_lechenii_bolnykh_sakharnym_diabetom_2_tipa.html?forgot_password=yes.; Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebocontrolled study. Curr Med Res Opin. 2009;25(10):2361–2371. https://doi.org/10.1185/03007990903156111.; DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebocontrolled study. Diabetes Care. 2008;31(12):2315–2317. https://doi.org/10.2337/dc08-1035.; Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab. 2013;15(10):906–914. https://doi.org/10.1111/dom.12102.; Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16(12):1239–1246. https://doi.org/10.1111/dom.12377.; Kaku K, Mori M, Kanoo T, Katou M, Seino Y. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opin Pharmacother. 2014;15(15):2121–2130. https://doi.org/10.1517/14656566.2014.956722.; Мкртумян АМ, Белолипецкий ЯА. Тандем алоглиптина и пиоглитазона – новый союз в борьбе с сахарным диабетом 2 типа. Эффективная фармакотерапия. 2021;17(31):18–36. Режим доступа: https://umedp.ru/upload/iblock/90f/Mkrtumyan.pdf.; Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, doubleblind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011;27(9):1781–1792. https://doi.org/10.1185/03007995.2011.599371.; Сидоров АВ. Клиническая фармакология ингибиторов дипептидилпептидазы 4: сравнительный обзор. Эффективная фармакотерапия. 2020;16(25):24–48. https://doi.org/10.33978/2307-3586-2020-16-25-24-48.; Van Raalte DH, van Genugten RE, Eliasson B, Möller-Goede DL, Mari A, Tura A et al. The effect of alogliptin and pioglitazone combination therapy on various Alogliptin: A Review aspects of beta-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170(4):565–574. https://doi.org/10.1530/EJE-13-0639.; Jurczyk A, Diiorio P, Brostowin D, Leehy L, Yang C, Urano F et al. Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rcnull mice treated with alogliptin. Diabetes Metab Syndr Obes. 2013;6:493–499 https://doi.org/10.2147/dmso.s53154.; Cavender MA, White BW, Liu Y, Massaro JM, Bergenstal RM, Mehta CR et al. Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. Clin Cardiol. 2018;41(8):1022–1027. https://doi.org/10.1002/clc.22960.; Katakami N, Mita T, Yoshii H, Onuma T, Kaneto H, Osonoi T et al. Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). J Atheroscler Thromb. 2013;20(12):893–902. https://doi.org/10.5551/jat.18333.; Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T et al. Alogliptin, a dipeptidyl peptidase-4 inhibitor prevents the progression of carotid atherosclerosis in patients with diabetes2 type: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care. 2015;39(1):139–148. https://doi.org/10.2337/dc15-0781.; Мкртумян АМ, Егшатян ЛВ. Алоглиптин – высокоселективный ингибитор ДПП-4 с фокусом на кардиоваскулярную безопасность. Медицинский совет. 2016;(5):104–107. Режим доступа: https://www.med-sovet.pro/jour/article/view/1335/1295.; Сухарева ОЮ, Шмушкович ИА, Шестакова ЕА, Шестакова МВ. Система инкретинов при сахарном диабете 2-го типа: сердечно-сосудистые эффекты. Проблемы эндокринологии. 2012;58(6):33–42. Режим доступа: https://www.probl-endojournals.ru/jour/article/view/61/12?locale=ru_RU.; Демидова ТЮ, Ушанова ФО, Жаркова ПО. Гликемические и негликемические преимущества применения фиксированной комбинации алоглиптина и пиоглитазона в управлении сахарным диабетом. FOCUS Эндокринология. 2021;(4):39–48. Режим доступа: https://endo-club.ru/upload/iblock/48c/48cfa4ea1d78aab62fd9677fcb4154e5.pdf.; Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin. 2011;27(3):21–29. https://doi.org/10.1185/03007995.2011.614936.; Eliasson B, Möller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012;55(4):915–925. https://doi.org/10.1007/s00125-011-2447-3.; Keating GM. Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs. 2015;75:777–796. https://doi.org/10.1007/s40265-015-0385-y.; Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406–2408. https://doi.org/10.2337/dc10-0159.; Bosi E, Ellis GC, Wilson CA, Fleck PR. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, activecontrolled, parallel-group study. Diabetes Obes Metab. 2011;13(12):1088–1096. https://doi.org/10.1111/j.1463-1326.2011.01463.x.; Van Raalte DH, van Genugten RE, Eliasson B, Möller-Goede DL, Mari A, Tura A et al. The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes. Eur J Endocrinol. 2014;170(4):565–574. https://doi.org/10.1530/EJE-13-0639.; Tomlinson B, Chan P, Lam CWK. An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2022;23(1):29–42. https://doi.org/10.1080/14656566.2021.1985465; Моргунов ЛЮ. Алоглиптин: эффективность, безопасность, новые возможности. Медицинский совет. 2020;(7):42–49. https://doi.org/10.21518/2079-701X-2020-7-42-49.; Салухов ВВ, Шипилова ДА, Минаков АА. Отдаленные результаты перевода пациентки с терапии агонистами рецепторов глюкагоноподобного пептида-1 в комбинации с метформином на ингибитор дипептидилпептидазы-4 в комбинации с пиоглитазоном и ингибитором натрийглюкозного котранспортера 2-го типа при сахарном диабете 2 типа. Сахарный диабет. 2024;27(1):104–109. https://doi.org/10.14341/DM13062.; Шестакова МВ, Анциферов МБ, Аметов АС, Галстян ГР, Демидова ТЮ, Зилов АВ и др. Какие новые возможности для клинической практики открывает исследование VERIFY и какова его ценность для пациентов с впервые выявленным СД 2 типа? Совместное заключение по итогам экспертного совета. 6 ноября 2019 г. Сахарный диабет. 2020;23(1):106–110. https://doi.org/10.14341/DM12404.; Pan C, Han P, Ji Q, Li C, Lu J, Yang J et al. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong. J Diabetes. 2017;9(4):386–395. https://doi.org/10.1111/1753-0407.12425.; Scheen AJ. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015;11(6):1005–1020. https://doi.org/10.1517/17425255.2015.1041499.; https://www.med-sovet.pro/jour/article/view/8267

الاتاحة: https://www.med-sovet.pro/jour/article/view/8267
https://doi.org/10.21518/ms2024-157

المؤلفون: D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, Yu. V. Gorbunova, A. V. Strygin, T. M. Andriashvili, A. A. Sokolova, N. S. Bolokhov, V. E. Pustynnikov, E. A. Fomichev

المصدر: Фармация и фармакология (Пятигорск), Vol 10, Iss 6, Pp 536-548 (2023)

مصطلحات موضوعية: ингибиторы дпп-4, ситаглиптин, доклинические исследования, сахарный диабет, аллоксан, стрептозотоцин, Therapeutics. Pharmacology, RM1-950

Relation: https://www.pharmpharm.ru/jour/article/view/1219; https://doaj.org/toc/2307-9266; https://doaj.org/toc/2413-2241; https://doaj.org/article/01e777c11d2e46abbb84447ee403e55c

الاتاحة: https://doi.org/10.19163/2307-9266-2022-10-6-536-548
https://doaj.org/article/01e777c11d2e46abbb84447ee403e55c

المؤلفون: I. Glinkina V., A. Balashova V., A. Shyman S., A. Oderij V., S. Khan A., G. Runova E., T. Morgunova B., V. Fadeev V., И. Глинкина В., А. Балашова В., А. Шыман С., А. Одерий В., С. Хан А., Г. Рунова Е., Т. Моргунова Б., В. Фадеев В.

المصدر: Meditsinskiy sovet = Medical Council; № 7 (2021); 56-67 ; Медицинский Совет; № 7 (2021); 56-67 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: elderly patient, type 2 diabetes, geriatric syndromes, polypharmacy, deprescribing, hypoglycaemia, DPP-4 inhibitors, vildagliptin, пожилой пациент, сахарный диабет 2-го типа, гериатрические синдромы, полипрагмазия, депрескрай-бинг, гипогликемия, ингибиторы ДПП-4, вилдаглиптин

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6142/5592; Ткачева О.Н., Котовская Ю.В., Рунихина Н.К., Фролова Е.В., Наумов А.В., Воробьева Н.М. и др. Клинические рекомендации «Старческая астения». Российский журнал гериатрической медицины. 2020;(1):11-46. doi:10.37586/2686-8636-1-2020-11-46.; American Diabetes Association. 12. Older Adults: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(1 Suppl.):S168-S179. doi:10.2337/dc21-S012.; Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018;21(3):144-159. doi:10.14341/DM9686.; LeRoith D., Biessels G.J., Braithwaite S.S., Casanueva F.F., Draznin B., Halter J.B. et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5): 1520-1574. doi:10.1210/jc.2019-00198.; Yakaryilmaz F.D., Ozturk Z.A. Treatment of Type 2 Diabetes Mellitus in the Elderly. World J Diabetes. 2017;8(6):278-285. doi:10.4239/wjd.v8.i6.278.; Kim K.S., Park S.W., Cho Y.W., Kim S.K. Higher Prevalence and Progression Rate of Chronic Kidney Disease in Elderly Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2018;42(3):224-232. doi:10.4093/dmj.2017.O065.; Jitraknatee J., Ruengorn C., Nochaiwong S. Prevalence and Risk Factors of Chronic Kidney Disease among Type 2 Diabetes Patients: A CrossSectional Study in Primary Care Practice. Sci Rep. 2020;10(1):1-10. doi:10.1038/s41598-020-63443-4.; Russo G.T., De Cosmo S., Viazzi F., Mirijello A., Ceriello A., Guida P. et al. Diabetic Kidney Disease in the Elderly: Prevalence and Clinical Correlates. BMCGeriatr. 2018;18(1):1-11. doi:10.1186/s12877-018-0732-4.; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом 9-й выпуск. Сахарный Диабет. 2019;22(1 Suppl.)1-144. doi:10.14341/DM221S1.; Bauduceau B., Le Floch J.P., Halimi S., Verny C., Doucet J. Cardiovascular Complications over 5 Years and Their Association with Survival in the GERODIAB Cohort of Elderly FRENCH Patients with Type 2 Diabetes. Diabetes Care. 2018;41(1):156-162. doi:10.2337/dc17-1437.; Schernthaner G., Schernthaner- Reiter M.H. Diabetes in the Older Patient: Heterogeneity Requires Individualisation of Therapeutic Strategies. Diabetologia. 2018;61(7):1503–1516. doi:10.1007/s00125-018-4547-9.; Longo M., Bellastella G., Maiorino M.I., Meier J.J., Esposito K., Giugliano D. Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. Front Endocrinol (Lausanne). 2019;10:45. doi:10.3389/fendo.2019.00045.; McCoy R.G., Lipska K.J., Yao X., Ross J.S., Montori V.M., Shah N.D. Intensive Treatment and Severe Hypoglycemia among Adults with Type 2 Diabetes. JAMA Intern Med. 2016;176(7):969-978. doi:10.1001/jamainternmed.2016.2275.; Zeyfang A., Patzelt- Bath A. Importance of Geriatric Syndromes in Older Patients with Diabetes with de novo Insulin Treatment: The VEGAS StudyDrugs Real World Outcomes. 2015;2(1):73–79. doi:10.1007/s40801-015-0014-9.; Ates Bulut E., Soysal P., Isik A.T. Frequency and Coincidence of Geriatric Syndromes According to Age Groups: Single-Center Experience in Turkey between 2013 and 2017. Clin IntersAging. 2018;13:1899-1905. doi:10.2147/CIA.S180281.; Gupta D., Kaur G., Gupta J.A. Geriatric Syndromes. In: Progress in Medicine 2016 (Medicine Update 2016). Vol. 26. New Delhi: Jaypee Brothers; 2016, pp. 1753-1758.; Ткачева О.Н., Фролова Е.В., Яхно Н.Н. Гериатрия. Национальное руководство. М.: ГЭОТАР-Медиа; 2019. 608 с.; Lewandowicz A., Skowronek P., Maksymiuk-Ktos A., Pietkiewicz P. The Giant Geriatric Syndromes Are Intensified by Diabetic Complications. Gerontol Geriatr Med. 2018;4:2333721418817396. doi:10.1177/2333721418817396.; Сычев Д.А. Полипрагмазия в клинической практике: проблема и решения. М.: ГБОУ ДПО РМАПО; 2016. 249 с. Режим доступа: http://irbis.rmapo.ru/UploadsFilesForIrbis/d5d7f99fb18dcb53a8f26f79dc33f17a.pdf.; Сычев Д.А., Бордовский С.П., Данилина К.С., Ильина Е.С. Потенциально не рекомендованные лекарственные средства для пациентов пожилого и старческого возраста: STOPP/START критерии. Клиническая фармакология и терапия. 2016;25(2):76-81. Режим доступа: https://clinpharm-journal.ru/articles/2016-2/potentsialno-nerekomendovannye-lekarstvennye-sredstva-dlya-patsientov-pozhilogo-i-starcheskogo-vozrasta-stopp-start-kriterii/?en=1.; Pham C.B., Dickman R.L. Minimizing Adverse Drug Events in Older Patients. Am Fam Physician. 2007;76(12):1837-1844. Available at: https://pubmed.ncbi.nlm.nih.gov/18217523/.; Fixen D.R. 2019 AGS Beers Criteria for Older Adults. Pharmacy Today. 2019;25(11):42-54. doi:10.1016/j.ptdy.2019.10.022.; O'Mahony D., O'Sullivan D., Byrne S., O'Connor M.N., Ryan C., Gallagher P. STOPP/START Criteria for Potentially Inappropriate Prescribing in Older People: Version 2. Age Ageing. 2015;44(2):213-218. doi:10.1093/ageing/afu145.; Lipska K.J., Ross J.S., Miao Y., Shah N.D., Lee S.J., Steinman M.A. Potential Overtreatment of Diabetes Mellitus in Older Adults with Tight Glycemic Control. JAMA Intern Med. 2015;175(3):356-362. doi:10.1001/jamainternmed.2014.7345.; Ткачева О.Н., Остроумова О.Д., Котовская Ю.В., Краснов П.С., Кочетков А.И., Переверзев А.П. Депрескрайбинг сахароснижающих препаратов у пациентов пожилого и старческого возраста: современное состояние вопроса и обзор доказательной базы. Клиническая фармакология и терапия. 2019;28(3):62-67. doi:10.32756/0869-5490-2019-3-62-67.; Reeve E., Denig P., Hilmer S.N., Ter Meulen R. The Ethics of Deprescribing in Older Adults. J Bioeth Inq. 2016;13(4):581-590. doi:10.1007/s11673-016-9736-y.; Farrell B., Black C., Thompson W., McCarthy L., Rojas-Fernandez C., Lochnan H. et al. Deprescribing Antihyperglycemic Agents in Older Persons: Evidence-Based Clinical Practice Guideline. Can Fam Physician. 2017;63(11):832-843. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685444/.; Ligthelm R.J., Kaiser M., Vora J., Yale J.F. Insulin Use in Elderly Adults: Risk of Hypoglycemia and Strategies for Care. J Am Geriatr Soc. 2012;60(8): 1564-1570. doi:10.1111/j.1532-5415.2012.04055.x.; Snell-Bergeon J.K., Wadwa R.P. Hypoglycemia, Diabetes, and Cardiovascular Disease. Diabetes Technol Ther. 2012;(14 Suppl.):S51-S58. doi:10.1089/dia.2012.0031.; Goto A., Arah O.A., Goto M., Terauchi Y., Noda M. Severe Hypoglycaemia and Cardiovascular Disease: Systematic Review and Meta-Analysis with Bias Analysis. BMJ. 2013;347:f4533. doi:10.1136/bmj.f4533.; Heller S.R., Bergenstal R.M., White W.B., Kupfer S., Bakris G.L., Cushman W.C. et al. Relationship of Glycated Haemoglobin and Reported Hypoglycaemia to Cardiovascular Outcomes in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome Events: The EXAMINE Trial. Diabetes Obes Metab. 2017;19(5):664-671. doi:10.1111/dom.12871.; The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 2008;358: 2545-2559. doi:10.1056/NEJMoa0802743.; Hanefeld M., Monnier L., Schnell O., Owens D. Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIn and Other Cardiovascular Trials. Diabetes Ther. 2016;7(2):187-201. doi:10.1007/s13300-016-0153-3.; Seidu S., Kunutsor S.K., Topsever P., Hambling C.E., Cos F.X., Khunti K. Deintensification in Older Patients with Type 2 Diabetes: A Systematic Review of Approaches, Rates and Outcomes. Diabetes Obes Metab. 2019;21(7):1668-1679. doi:10.1111/dom.13724.; Haas L.B. Special Considerations for Older Adults with Diabetes Residing in Skilled Nursing Facilities. Diabetes Spectr. 2014;27(1):37-43. doi:10.2337/diaspect.27.1.37.; Мисникова И.В., Ковалева Ю.А., Исаков М.А., Древаль А.В. Структура сахароснижающей терапии в особых группах пациентов с сахарным диабетом 2-го типа на основании данных регистра Московской области. Сахарный диабет. 2019;22(3):206-216. doi:10.14341/DM10084.; Yamamoto-Honda R., Takahashi Y., Mori Y., Yamashita S., Yoshida Y., Kawazu S. et al. Changes in Antidiabetic Drug Prescription and Glycemic Control Trends in Elderly Patients with Type 2 Diabetes Mellitus from 2005-2013: An Analysis of the National Center Diabetes Database (NCDD-03). Intern Med. 2018;57(9):1229-1240. doi:10.2169/internalmedicine.9481-17.; Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D. et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med. 2009;360(2):129-139. doi:10.1056/NEJMoa0808431.; Heller S.R. A summary of the ADVANCE Trial. Diabetes Care. 2009;(32 Suppl.): S357-S361. doi:10.2337/dc09-S339.; American Diabetes Association. Standards of Medical Care in Diabetes 2010. Diabetes Care. 2010;(33 Suppl.):S11-S61. doi:10.2337/dc10-S011.; Black C.D., Thompson W., Welch V., McCarthy L., Rojas-Fernandez C., Lochnan H. et al. Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review. Diabetes Ther. 2017;8(1):23-31. doi:10.1007/s13300-016-0220-945.; Bohannon N. Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice. Postgrad Med. 2009;121(1):40-45. doi:10.3810/pgm.2009.01.1953.; Сидоров А.В. Клиническая фармакология ингибиторов дипептидилпепти-дазы 4: сравнительный обзор. Эффективная фармакотерапия. 2020;16(25):24-48. doi:10.33978/2307-3586-2020-16-25-24-48.; Rathmann W., Kostev K., Gruenberger J.B., Dworak M., Bader G., Giani G. Treatment Persistence, Hypoglycaemia and Clinical Outcomes in Type 2 Diabetes Patients with Dipeptidyl Peptidase-4 Inhibitors and Sulphonylureas: A Primary Care Database Analysis. Diabetes Obes Metab. 2013;15(1):55-61. doi:10.1111/j.1463-1326.2012.01674.x.; Gitt A.K., Bramlage P., Binz C., Krekler M., Deeg E., Tschope D. Prognostic Implications of DPP-4 Inhibitor vs. Sulfonylurea Use on Top of Metformin in a Real World Setting - Results of the 1 Year Follow-Up of the Prospective DiaRegis Registry. Int J Clin Pract. 2013;67(10):1005-1014. doi:10.1111/ijcp.12179.; Strain W.D., Lukashevich V., Kothny W., Hoellinger MJ., Paldanius P.M. Individualised Treatment Targets for Elderly Patients with Type 2 Diabetes Using Vildagliptin Add-On or Lone Therapy (INTERVAL): A 24 Week, Randomised, Double-Blind, Placebo-Controlled Study. Lancet. 2013;382(9890):409-416. doi:10.1016/S0140-6736(13)60995-2.; Russo E., Penno G., Del Prato S. Managing Diabetic Patients with Moderate or Severe Renal Impairment Using DPP-4 Inhibitors: Focus on Vildagliptin. Diabetes Metab Syndr Obes. 2013;6:161-170. doi:10.2147/DMSO.S28951.; Matthews D.R., Paldanius P.M., Proot P., Chiang Y.T., Stumvoll M., Del Prato S. Glycaemic Durability of an Early Combination Therapy with Vildagliptin and Metformin versus Sequential Metformin Monotherapy in Newly Diagnosed Type 2 Diabetes (VERIFY): A 5-Year, Multicentre, Randomised, Double-Blind Trial. Lancet. 2019;394(10208):1519-1529. doi:10.1016/S0140-6736(19)32131-2.; Krishnaswami A., Steinman M.A., Goyal P., Zullo A.R., Anderson T.S., Birtcher K.K. et al. Geriatric Cardiology Section Leadership Council, American College of Cardiology. Deprescribing in Older Adults with Cardiovascular Disease. J Am Coll Cardiol. 2019;73(20):2584-2595. doi:10.1016/j.jacc.2019.03.467.53.; Watts N.B., Bilezikian J.P., Usiskin K., Edwards R., Desai M., Law G. et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016;101(1):157-166. doi:10.1210/jc.2015-3167.; https://www.med-sovet.pro/jour/article/view/6142

الاتاحة: https://www.med-sovet.pro/jour/article/view/6142
https://doi.org/10.21518/2079-701X-2021-7-56-67

المؤلفون: Mykhalchyshyn, Halyna

المصدر: Family Medicine; No. 5-6 (2020); 79-83 ; Семейная медицина; № 5-6 (2020); 79-83 ; Сімейна медицина; № 5-6 (2020); 79-83 ; 2412-8708 ; 2307-5112

مصطلحات موضوعية: сахарный диабет 2-го типа, неалкогольная жировая болезнь печени, ингибиторы ДПП-4, статины, пробиотики, 616.379-008.64-03 616.36-003.826]-092:614.2]-043.74, цукровий діабет 2-го типу, неалкогольна жирова хвороба печінки, інгібітори ДПП-4, статини, пробіотики, diabetes mellitus type two, nonalcoholic fatty liver disease, DPP-4 inhibitor, statins, probiotic

وصف الملف: application/pdf

Relation: http://family-medicine.com.ua/article/view/225464/225284; http://family-medicine.com.ua/article/view/225464

الاتاحة: http://family-medicine.com.ua/article/view/225464
https://doi.org/10.30841/2307-5112.5-6.2020.225464

المصدر: Качественная клиническая практика, Vol 0, Iss 1, Pp 76-82 (2018)

مصطلحات موضوعية: сахарный диабет 2 типа, ингибиторы дпп-4, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

وصف الملف: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/157; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

URL الوصول: https://doaj.org/article/448611dde8844994a0a74375bd31284b

المؤلفون: S. V. Nedogoda, I. N. Sorokina, A. S. Salasiuk, V. O. Smirnov

المصدر: Качественная клиническая практика, Vol 0, Iss 4, Pp 43-52 (2018)

مصطلحات موضوعية: сахарный диабет 2-го типа, ингибиторы дпп-4, анализ эффективности затрат, анализ полезности затрат, алоглиптин, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

وصف الملف: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/112; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

URL الوصول: https://doaj.org/article/2f7bed18993847459876939eb50173b7

المؤلفون: L. Y. Morgunov

المصدر: Медицинский совет, Vol 0, Iss 3, Pp 92-97 (2016)

مصطلحات موضوعية: вилдаглиптин, ингибиторы дпп-4, сахарный диабет 2-го типа, безопасность, vildagliptin, dpp-4 inhibitors, type 2 diabetes, safety, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/66; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/feeaf9017596420684ef691b4cc88f7e

المؤلفون: A. L. Terekhova, N. A. Petunina

المصدر: Медицинский совет, Vol 0, Iss 3, Pp 38-47 (2016)

مصطلحات موضوعية: алоглиптин, ингибиторы дпп-4, эффективность, безопасность, сердечно-сосудистые события, гипогликемия, випидия, alogliptin, vipidiya, dpp-4 inhibitors, efficacy, safety, cardiovascular events, hypoglycemia, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/57; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/f59db13f05d5447f9f4a9f112942e995

المؤلفون: P. Shorokhova B., V. Baranov L., N. Vorokhobina V., I. Matezius Yu., E. Bashnina B., K. Jakovenko A., П. Шорохова Б., В. Баранов Л., Н. Ворохобина В., И. Матезиус Ю., Е. Башнина Б., К. Яковенко А.

المصدر: Medical Herald of the South of Russia; Том 10, № 3 (2019); 83-90 ; Медицинский вестник Юга России; Том 10, № 3 (2019); 83-90 ; 2618-7876 ; 2219-8075 ; 10.21886/2219-8075-2019-10-3

مصطلحات موضوعية: type 2 diabetes mellitus, glycated hemoglobin, polymorphism rs5219, KCNJ11 gene, dpp-4 inhibitors, сахарный диабет 2 типа, гликированный гемоглобин, полиморфизм rs5219, ген KCNJ11, ингибиторы ДПП-4

وصف الملف: application/pdf

Relation: https://www.medicalherald.ru/jour/article/view/925/530; DeFronzo R.A. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. // Diabetes. – 2009. – V.58(4). – P.773–795. doi:10.2337/db09-9028.; Schwartz S.S., Epstein S., Corkey B.E., Grant S.F.A., Gavin J.R., Aguilar R.B. The time is right for a new classification system for diabetes: rationale and implications of the β-cell–centric classification schema. // Diabetes Care. – 2016. – V.39(8). – P. 179–186. http://doi.org/10.2337/dci16-0011.; Демидова Т.Ю., Куленок С.Г., Гасанзаде П.А. Патогенетические предпосылки применения ингибиторов дипептидилпептидазы-4 в управлении сахарным диабетом типа 2 // Consilium Medicum. – 2017. – Т. 19, № 4 – С. 23–28. https://doi.org/10.26442/2075-1753_19.4.23-28.; Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. // Diabetologia. – 2007. – V.50(6). – P. 1148–1155. https://doi.org/10.1007/s00125-007-0633-0; Дедов И.И, Шестакова М.В, Аметов А.С, Анциферов М.Б., Галстян Г.Р., Майоров А.Ю. и др. Инициация и интенсификация сахароснижающей терапии у больных сахарным диабетом 2 типа: обновление консенсуса совета экспертов Российской ассоциации эндокринологов (2015) // Сахарный диабет. – 2015. – Т. 18., № 1. – С. 5-23. doi:10.14341/DM201515-23.; Aso Y., Ozeki N., Terasawa T., Naruse R., Hara K., Suetsugu M., et al. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. // Transl Res. – 2012. – V.159(1). – P. 25–31. doi:10.1016/j.trsl.2011.09.005.; Semiz S., Dujic T., Causevic A. Pharmacogenetics and personalized treatment of type 2 diabetes. // Biochem.Med. – 2013. – V.23(2). – P.154–171. doi:10.11613/BM.2013.020.; Jamaluddin J.L., Huri H.Z., Vethakkan S.R., Mustafa N. Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes. // Pharmacogenomics. – 2014. – V.15(2). – P. 235–249. http://doi.org/10.2217/pgs.13.234.; Dawed A.Y., Zhou K., Pearson E.R. Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents. // Pharmacogenomics and Personalized Medicine. – 2016. – V.9. – P.17–29. https://doi.org/10.2147/PGPM.S84854.; Haghvirdizadeh P., Mohamed Z., Abdullah N.A., Haghvirdizadeh P., Haerian M.S., Haerian B.S. KCNJ11: Genetic Polymorphisms and Risk of Diabetes Mellitus. // J Diabetes Res. – 2015. – V.2015. – P.1-9. doi:10.1155/2015/908152.; Jamaluddin J.L., Huri H.Z., Vethakkan S.R. Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in type 2 diabetes mellitus. // Pharmacogenomics. – 2016. – V.17(8). – P.867–881. doi:10.2217/pgs-2016-0010.; Методы статистической обработки медицинских данных: Методические рекомендации для ординаторов и аспирантов медицинских учебных заведений, научных работников / сост.: Кочетов А.Г., Лянг О.В., Масенко В.П., Жиров И.В., Наконечников С.Н., Терещенко С.Н. – М.: РКНПК, 2012. – 42 с.; Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. // Diabetologia. – 2015. – V.58(3). – P.429-442. doi:10.1007/s00125-014-3460-0; Ashcroft FM, Rorsman P. K(ATP) channels and islet hormone secretion: new insights and controversies. // Nat Rev Endocrinol. – 2013. – V.9(11). – P.660–669. doi:10.1038/nrendo.2013.166; Sastre J, Luque A, del Val F, Aragonés A, López J. Long-term efficacy of glibenclamide and sitagliptin therapy in adult patients with KCNJ11 permanent diabetes. // Diabetes Care. – 2014. – V.37(3). – P.e55-56. doi:10.2337/dc13-2280; https://www.medicalherald.ru/jour/article/view/925

الاتاحة: https://www.medicalherald.ru/jour/article/view/925
https://doi.org/10.21886/2219-8075-2019-10-3-83-90

المؤلفون: N. Petunina A., A. Terekhova L., Н. Петунина А., А. Терехова Л.

المصدر: Meditsinskiy sovet = Medical Council; № 21 (2018); 138-145 ; Медицинский Совет; № 21 (2018); 138-145 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-21

مصطلحات موضوعية: alogliptin, metformin, DPP-4 inhibitors, combination therapy, Vipdomet®, fixed-dose combination therapy, efficacy, safety, алоглиптин, метформин, ингибиторы ДПП-4, комбинированная терапия, Випдомет®, фиксированная комбинация, эффективность, безопасность

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2828/2772; International Diabetes Federation. IDF Diabetes Atlas 7th ed., 2015. http://www.idf.org/diabetesatlas.; Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-112. doi:10.14341/DM2004116-17.; Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития. Сахарный диабет. 2015;18(3):5-22. doi:10.14341/DM201535-22.; Global health risks: mortality and burden of disease attributable to selected major risks. Geneva: World Health Organization; 2009. Available from: http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf.; Ali M.K., Bullard K.M., Gregg E.W., Del Rio C. A cascade of care for diabetes in the United States: visualizing the gaps. Ann Intern Med. 2014;161:681–9.; Stark Casagrande S., Fradkin J.E., Saydah S.H., Rust K.F., Cowie C.C. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013;36:2271–2279.; Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю., Колбин A.C., Рафальский В.В., Чеберда А.Е., Кантемирова М.А., Закиев В.Д., Фадеев В.В. Анализ стоимости болезни сахарного диабета 2 типа в Российской Федерации: результаты российского многоцентрового наблюдательного фармакоэпидемиологического исследования ФОРСАЙТ-СД2. Сахарный диабет. 2017;20(6):403-419. doi:10.14341/DM9278.; DeFronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–95. https://doi.org/10.2337/db09-9028.; Zonszein Joel, Groop Per-Henrik Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. Diabetes Ther. 2016;7:621–639. doi:10.1007/s13300-016-0208-5.; Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 8-й выпуск. Сахарный диабет. 2017;20(1S):1-121.; Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149. doi:10.2337/dc14-2441; Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2018 Executive Summary. 2018 AACE/ACE T2D Managemen. Endocr Pract. 2018;24(1):91-120.; Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018. American Diabetes Association. Diabetes Care. 2018 Jan;41(Supplement 1):S73-S85. https://doi.org/10.2337/dc18-S008.; Дедов И.И., Шестакова М.В. Феномен «метаболической памяти» в прогнозировании риска развития сосудистых осложнений при сахарном диабете. Терапевтический архив. 2015;87(10):4-10.; Phung O.J., Sobieraj D.M., Engel S.S., Rajpathak S.N. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:410–17.; Phillips L.S., Ratner R.E., Buse J.B., Kahn S.E. We can change the natural history of type 2 diabetes. Diabetes Care. 2014;37:2668–2676.; Lavernia F., Adkins SE., Shubrook JH. Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals. Postgraduate Medicine, 2015;127:8, 808- 817. doi:10.1080/00325481.2015.1085293.; Food and Drug Administration, Center for Drug Evaluation and Research Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type-2 diabetes. 2008 Dec; Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf. Accessed February 9, 2014.; Karagiannis T., Paschos P., Paletas K., Matthews D.R., Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and metaanalysis. BMJ. 2012 Mar 12;344:e1369. doi:10.1136/bmj.e1369.; Abdulrahman S. Alanazi Saudi. Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors. Pharmaceutical Journal. 2015;23:603–613. https://doi.org/10.1016/j.jsps.2013.12.018.; Deacon C.F., Mannucci E., Ahrén B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes – a review and meta analysis. Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi:10.1111/j.1463-1326.2012.01603.x.; Huang E.S., Karter A.J., Danielson K.K., Warton E.M., Ahmed A.T. The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the diabetes and aging study. J Gen Intern Med. 2010;25(2):141–6.; UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–13.; Frye R.L., August P., Brooks M.M., et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.; Ho P.M., Rumsfeld J.S., Masoudi F.A., et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836–41.; McGovern A., Tippu Z., Hinton W., et al. Systematic review of adherence rates by medication class in type 2 diabetes: a study protocol. BMJ Open. 2016;6:e010469. doi:10.1136/bmjopen-2015-010469.; Luis-Emilio Garcı´a-Pe´rez, Marı´a A´ lvarez, Tatiana Dilla et al. Adherence to Therapies in Patients with Type 2 Diabetes. Diabetes Ther. 2013;4:175–194. Doi:10.1007/s13300-013-0034-y.; Hutchins V., Zhang B., Fleurence R.L., Krishnarajah G., Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27:1157–68.; Cheong C., Barner J.C., Lawson K.A., Johnsrud M.T. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther. 2008;30:1893–907.; Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–24.; Blonde L., San Juan Z.T., Bolton P. Fixed-dose combination therapy in type 2 diabetes mellitus. Endocr Pract. 2014;20(12):1322–32.; Blonde L., San Juan Z.T. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther. 2012;29(1):1–13.; Blonde L., Wogen J., Kreilick C., Seymour A.A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide coadministered with metformin. Diabetes Obes Metab. 2003;5(6):424–31.; Han S., Iglay K., Davies M.J., Zhang Q., Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin. 2012;28:969–77.; Liu Y., Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab. 2014;16:111–17.; Harpreet S. Bajaj, Chenglin Ye, Esha Jain, Karri Venn, Eden Stein, Ronnie Aronson. Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study). Diabetes Obes Metab. 2017;1–5. doi:10.1111/dom.13040.; Руяткина Л.А., Руяткин Д.С. Многоплановые эффекты метформина у пациентов с сахарным диабетом 2 типа. Сахарный диабет. 2017;20(3):210-219. doi:10.14341/DM2003458-64.; Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed June 16, 2016; Глюкофаж 500/850/1000 мг – официальная инструкция по применению, электронный ресурс https://medi.ru/instrukciya/glyukofazh-500-800-1000_9567/; Aguilar D., Chan W., Bozkurt B., et al. Metformin Use and Mortality in Ambulatory Patients with Diabetes and Heart Failure. Circ Heart Fail. 2011;4(1):53–58. doi:10.1161/CIRCHEARTFAILURE.110.952556.; Papanas N., Maltezos E., Mikhailidis D.P. Metformin and heart failure: never say never again. Expert Opin Pharmacother. 2012;13(1):1-8. doi:10.1517/14656566.2012.638283.; Crowley M.J., Diamantidis C.J., McDuffie J.R., et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. Ann Intern Med. 2017;166(3):191-200. doi:10.7326/M16-1901.; Kutoh E., Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naıve type 2 diabetes: a randomized, control trial. Endocrine.2012;41(3):435–441.; Seino Y., Fujita T., Hiroi S., Hirayama M., Kaku K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011;27(9):1781–1792.; DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin Study 010 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, doubleblind, placebo-controlled study. Diabetes Care. 2008;31(12):2315–2317.; Rosenstock J., Inzucchi S.E., Seufert J., Fleck P.R., Wilson G.A., Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drugnaïve patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406–2408.; Pratley R., Wilson C., Fleck P. Alogliptin plus metformin combination therapy vs. alogliptin or metformin monotherapy for type 2 DM (abstract). Presented at 48th Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany. October 2012.; Nauck M.A., Ellis G.C., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin Study 008 Group Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46–55.; Kaku K., Itayasu T., Hiroi S., Hirayama M., Seino Y. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebocontrolled trial with an open-label long-term extension study. Diabetes Obes Metab. 2011;13(11):1028–1035.; Pratley R.E., Reusch J.E., Fleck P.R., Wilson C.A., Mekki Q., Alogliptin Study 009 Group Efficacy and safety of the dipeptidyl peptidase- 4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009;25(10):2361–2371.; Bosi E., Ellis G.C., Wilson C.A., Fleck P.R. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, doubleblind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011;13(12):1088–1096.; Pratley R.E., Kipnes M.S., Fleck P.R., Wilson C., Mekki Q. Alogliptin Study 007 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 2009;11(2):167–176.; Seino Y., Fujita T., Hiroi S., Hirayama M., Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled trial with an openlabel, long-term extension. Curr Med Res Opin. 2011;27(Suppl 3):21–29.; Rosenstock J., Rendell M.S., Gross J.L., et al. Alogliptin added to insulin therapy in patients with type-2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia. Diabetes Obes Metab. 2009;11:1145–1152.; Asres Berhan and Yifru Berhan. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocrine Disorders. 2013;13:9. http://www.biomedcentral.com/1472-6823/13/9.; Capuano A., Sportiello L, Maiorino M, Rossi F et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Des Devel Ther. 2013;7:989–1001. doi:10.2147/DDDT.S37647.; Seino Y., Miyata Y., Hiroi S., Hirayama M., Kaku K. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebocontrolled trial with an open-label, long-term extension study. Diabetes Obes Metab. 2012;14(10):927–936.; Del Prato S., Camisasca R., Craig Wilson et al. Durability of the Efficacy and safety of Alogliptin Compared to Glipizide over 2 Years When Used in Combination with Metformin. Poster 66-LB presented at the 73rd Scientific Sessions of the American Diabetes Association (ADA), Chicago, Illinois, June 21-25, 2013.; Seino Y., Hiroi S., Hirayama K., Kaku K. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. J Diabetes Invest. 2012;3:517-25.; White W.B., Bakris G.L., Bergenstal R.M., et al. EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162(4):620–626.; Hall C Alogliptin in patients with type 2 diabetes after acute coronary syndromes: heart failure utcomes and cardiovascular safety in heart failure patients. JACC. 2014 April 1; 63(12).; Fujita H., Tania H., Murayama H. et al. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients ith incipient nephropathy. Endocrine Journal. 2014;61(2):159-166. doi:10.1507/endocrj.EJ13-0305).; Pratley R.E., McCall T., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. J Am Geriatr Soc. 2009 Nov;57(11):2011-9. doi:10.1111/j.1532-5415.2009.02484.x.; Rosenstock J., Wilson C., Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double blind, randomized, 1-year study. Diabetes Obes Metab. 2013;15(10):906–914. PMID: 23531118. doi:10.1111/dom.12102.; Christopher R., Karim A. Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes. Expert Review of Clinical Pharmacology. 2009;2(6):589–600. PMID: 22112254. doi:10.1586/ecp.09.45.; Jianying Fu, Jianhong Zhu, Yehua Hao, Chongchong Guo, and Zhikun Zhoua. Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci Rep. 2016;6: 29104. doi:10.1038/srep29104. PMCID: PMC4935882.; Pratley R.E., Fleck P., Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab. 2014 Jul;16(7):613-21. doi:10.1111/dom.12258.; Alogliptin Plus Metformin (Kazano) for Type 2 Diabetes Mellitus. CDR submission: Kazano™ (alogliptin and metformin) 12.5 mg/500 mg, 12.5 mg/850 mg and 12.5 mg/1000 mg tablets. Company: Takeda Canada Inc. [CONFIDENTIAL manufacturer’s submission]. Oakville (ON): Takeda Canada Inc; Dec, 2013. электронный ресурс - https://www.ncbi.nlm.nih.gov/books/NBK349220/; Linong Ji, Ling Li, Jian Kuang, Tao Yang, DongJun Kim, Azidah A.Kadir, Chien-Ning Huang, Douglas Lee Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial. Diabetes Obes Metab. 2017;19:754–758. Doi:10.1111/dom.12875.; https://www.med-sovet.pro/jour/article/view/2828

الاتاحة: https://www.med-sovet.pro/jour/article/view/2828
https://doi.org/10.21518/2079-701X-2018-21-138-145

المؤلفون: В. В. Скворцов, А. В. Тумаренко

المصدر: Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice; № 1 (2012); 76-82 ; Качественная клиническая практика; № 1 (2012); 76-82 ; 2618-8473 ; 2588-0519

مصطلحات موضوعية: ингибиторы ДПП-4

وصف الملف: application/pdf

Relation: https://www.clinvest.ru/jour/article/view/157/159; Аметов А. С. Сахарный диабет 2 типа . Основы патогенеза и терапии . Москва, 2003 .; Аметов А.С., Демидова Т. Ю., Доскина Е. В., Черникова Н. А. Алгоритм диагностики и управления сахарным диабетом 2 типа . Клинические рекомендации для практикующих врачей . Москва, 2007 .; Дедов И.И., Шестакова М. В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом . Москва, 2007 .; Fonseca V., at al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes . Diabetologia . 2007; 50:1148–1155 .; Fonseca V., Dejager S., Albrecht S. et al. Vildagliptin as add–on to insulin in patients with type 2 diabetes (T2DM) . Diabetes 2006; 55 (suppl 1): A111 .; Garber A.G., et al. Efficacy and Tolerability of Vildagliptin Added to a Sulfonylurea in Patients with Type 2 Diabetes . Presented at ADA, 22–26 June 2007 (Abstract 501–P) .; Croxtall J.D., Keam S. J. Vildagliptin: a review of use in the management of type 2 diabetes mellitus . Drugs 2008; 68 (16): 2387–2409 .; Halimi S., Schweizer A., Minic B. et al. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet . Vascular Health and Risk Management 2008; 4 (3): 481–492 .; Материалы сайтов health-ua.com, health-ua.org .; https://www.clinvest.ru/jour/article/view/157

الاتاحة: https://www.clinvest.ru/jour/article/view/157

المصدر: Качественная клиническая практика, Vol 0, Iss 1, Pp 76-82 (2018)

مصطلحات موضوعية: сахарный диабет 2 типа, ингибиторы дпп-4, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

Relation: https://www.clinvest.ru/jour/article/view/157; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473; https://doaj.org/article/448611dde8844994a0a74375bd31284b

الاتاحة: https://doaj.org/article/448611dde8844994a0a74375bd31284b

المؤلفون: N. A. Petunina, E. V. Goncharova, S. A. Potapova, Н. А. Петунина, Е. В. Гончарова, С. А. Потапова

المصدر: Meditsinskiy sovet = Medical Council; № 3 (2017); 32-37 ; Медицинский Совет; № 3 (2017); 32-37 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-3

مصطلحات موضوعية: глиптины, diabetes, DPP-4 inhibitors, gliptins, сахарный диабет, ингибиторы ДПП-4

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1746/1690; IDF Diabetes Atlas – Seventh Edition, 2015. Online version of IDF Diabetes Atlas. Доступно по: www.diabetesatlas.org.; Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». Сахарный диабет, 2015, 18(1S): 1-112.; Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia, 2002, 45(7): 937-948.; Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med, 2009, 360: 129-139.; FDA. Guidance for industry: diabetes mellitusevaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Доступно по: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.; Elrick H, Stimmler L, Hlad CJ, Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab, 1964, 24(10): 1076–1082.; Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med, 1992, 326(20): 1316–1322.; Потапова С.А., Гончарова Е.В., Петунина Н.А. Сравнительная характеристика кардиоваскулярной безопасности сахароснижающих препаратов. Лечебное дело, 2016, 2: 76-88.; Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Des Devel Ther, 2013, 7: 989-1001. doi:10.2147/DDDT.S37647.; Herman GA, Bergman A, Yi B, Kipnes M, Sitagliptin Study 012 Group. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when coadministered in patients with type 2 diabetes. Curr Med Res Opin, 2006, 22: 1939-1947.; He YL, Sabo R, Picard F, Wang Y, Herron J, Ligueros-Saylan M, Dole WP. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin, 2009, 25: 1265-1272.; Mistry GC, Bergman AJ, Zheng W, Hreniuk D, Zinny MA, Gottesdiener KM, Wagner JA, Herman GA, Ruddy M. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol, 2008, 66: 36–42.; Mistry GC, Bergman AJ, Luo WL, Cilissen C, Haazen W, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol, 2007, 47: 159–164.; Karim A, Laurent A, Munsaka M, Wann E, Fleck P, Mekki Q. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol, 2009, 49: 1210-1219.; Berndt-Zipfel C, Michelson G, Dworak M, Mitry M, Löffler A, Pfützner A, Forst T. Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus–results from an exploratory study. Cardiovasc Diabetol, 2013, 12: 59.; Graefe-Mody U, Huettner S, Stähle H., Ring A., Dugi K.A. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther, 2010, 48: 367-374.; Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev, 2012, 33: 187-215.; Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res, 2012, 9: 109-116.; White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab, 2013, 15: 668-673.; Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin, 2011, 27(Suppl 3): 57-64.; Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med, 2007, 356: 2457-2471.; Roumie CL, Hung AM, Greevy RA et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med, 2012, 157: 601-610.; Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2015, 373: 232-242.; Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol, 2013, 12: 3.; Nathewani A, Lebault A, Byiers S, Gimpelewicz C, Chang IH. Reduction in blood pressure in patients treated with vildagliptin as monotherapy or in combination with metformin for type 2 diabetes. Program and abstracts of the Ame rican Diabetes Association 66th Scientific Sessions, Washington, DC. June 9-13, 2006. 474 p.; Diess D, Bosi E, Riveline JP, Battelino T, Bosi E, Tubiana-Rufi N, Kerr D, Phillip M. Improved glycemic control in poorly controlled patients with type 1diabetes using real-time continuous glucose monitoring. Diabetes Care, 2006, 29: 2730-2732.; Matikainen N, Mänttäri S, Schweizer A, Ulvestad A, Mills D, Dunning BE, Foley JE, Taskinen MR. Vildaglip tin therapy reduces postprandial intestinal triglyceride rich lipoprotein particles in patients with type 2 diabetes. Diabetologia, 2006, 49(9): 2049-2057.; Ligueros-Saylan M, Schweizer A, Dickinson S, Kothny W. Vildagliptin therapy is not associated with an increased risk of pancreatitis. EASD Poster presentation. 2009.; He Y-L, Sabo R, Riviere GJ, Sunkara G, Leon S, Ligueros-Saylan M, Rosenberg M, Dole WP, Howard D. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin, 2007, 23: 1131-1138.; Ayalasomayajula SP, Dole K, He YL, LiguerosSaylan M, Wang Y, Campestrini J, Humbert H, Sunkara G. Evaluation of the potential for steadystate pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. CurrMed Res Opin, 2007, 23(12): 2913-2920.; McInnes G, Evans M, Del Prato S, Stumvoll M, Schweizer A, Lukashevich V, Shao Q, Kothny W. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17000 patients. Diabetes Obes Metab, 2015, 17(11): 1085-1092.; Hong AR, Lee J, Ku EJ, Hwangbo Y, Kim KM, Moon JH, Choi SH, Jang HC, Lim S. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial. Diabetes Res Clin Pract, 2015, 109: 141-148.; Forst T, Koch C, Dworak M. Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study. Curr Med Res Opin, 2015, 31: 1079-1084.; Ishii M, Shibata R, Kondo K, Kambara T, Shimizu Y, Tanigawa T, Bando YK, Nishimura M, Ouchi N, Murohara T. Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitricoxide synthase-dependent mechanism. J Biol Chem, 2014, 289: 27235–27245.; Miyoshi T, Nakamura K, Yoshida M, Miura D, Oe H, Akagi S, Sugiyama H, Akazawa K, Yonezawa T, Wada J, Ito H. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic betaadrenergic stimulation in rats. Cardiovasc Diabetol, 2014, 13: 43.; Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med, 2013, 369: 1317-1326.; Steering Committee and Investigators. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care, 2015, 38: 1145-1153.; Eurich DT, Weir DL, Simpson SH, Senthilselvan A, McAlister FA. Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study. Diabet Med, 2015, 33(5): 621-630.; Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL, SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation, 2014, 130: 1579-1588.; Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: metaanalysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther, 2014, 32(4): 147-158.; Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, Johansen OE. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol, 2015, 14: 57.; Rosenstock J, Marx N, Kahn SE, Zinman B, Kas telein JJ, Lachin JM, Bluhmki E, Patel S, Johan sen OE, Woerle HJ. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res, 2013, 10: 289-301.; Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes: CAROLINA®. Diab Vasc Dis Res, 2015, 12: 164-174.; FDA doctor. Clinical Trial CARMELINA Study with Linagliptin in Patients with Type II Diabetes. 2015. http://fdadoctor.com/clinicaltrial-carmelina-study-with-linagliptin-inpatients-with-type-ii-diabetes/.; Groop P-H, Cooper ME, Perkovic V, Emser A, Woerle H-J, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care, 2013, 36: 3460-3468.; Von Eynatten M, Gong Y, Emser A, Woerle H-J. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc Diabetol, 2013, 12: 60.; McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, Woerle HJ. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care, 2013, 36: 237-244.; Koibuchi N, Hasegawa Y, Katayama T, Toyama K, Uekawa K, Sueta D, Kusaka H, Ma M, Nakagawa T, Lin B, Kim-Mitsuyama S. DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc Diabetol, 2014, 13: 157.; Terawaki Y, Nomiyama T, Kawanami T, Hamaguchi Y, Takahashi H, Tanaka T, Murase K, Nagaishi R, Tanabe M, Yanase T. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol, 2014, 13: 154.; Covington P, Christopher R, Davenport M, Fleck P, Karim A. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhi bitor alogliptin: a randomized, double-mind, placebocontrolled, multiple-dose study in adult pati ents with type 2 diabetes. Clin Ther, 2008, 30: 499-512.; Ndefo UA, Okoli O, Erowele G. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. Am J Health Syst Pharm, 2014, 71: 103-109.; Jarvis CI, Cabrera A, Charron D. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann Pharmacother, 2013, 47: 1532-1539.; Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study 008 Group Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract, 2009, 63(1): 46-55.; Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study 009 Group Efficacy and safety of the dipeptidyl pepti-dase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin, 2009, 25(10): 2361–2371.; Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q, Alogliptin Study 007 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab, 2009, 11(2): 167-176.; Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled trial with an openlabel, long-term extension. Curr Med Res Opin, 2011, 27(Suppl 3): 21-29.; Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab, 2009, 11(12): 1145-1152.; White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. Examination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J, 2011, 162: 620-626.; Pratley RE. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother, 2009, 10: 503-512.; Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, 2015, 385: 2067-2076.; Kaku K, Katou M, Igeta M, Ohira T, Sano H. Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group, comparative study. Diabetes Obes Metab, 2015, 17(12): 1198-1201.; DeFronzo RA, Fleck PR, Wilson CA, Mekki Q, on behalf of the Alogliptin Study 010 Group. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebocontrolled study. Diabetes Care, 2008, 31(12): 2315-2317. doi:10.2337/dc08-1035.; Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab, 2014, 16: 1239-1246. doi:10.1111/dom.12377.; Терехова А.Л., Петунина Н.А. Кардиоваскулярная безопасность в терапии сахарного диабета 2-го типа: Фокус на алоглиптин. Медицинский Совет, 2016, 3: 38-46.; https://www.med-sovet.pro/jour/article/view/1746

الاتاحة: https://www.med-sovet.pro/jour/article/view/1746
https://doi.org/10.21518/2079-701X-2017-3-32-37

المصدر: Сімейна медицина; № 5-6 (2020); 79-83
Family Medicine; No. 5-6 (2020); 79-83
Семейная медицина; № 5-6 (2020); 79-83

مصطلحات موضوعية: nonalcoholic fatty liver disease, 616.379-008.64-03 616.36-003.826]-092:614.2]-043.74, пробиотики, пробіотики, цукровий діабет 2-го типу, неалкогольная жировая болезнь печени, статини, statins, сахарный диабет 2-го типа, ингибиторы ДПП-4, статины, інгібітори ДПП-4, неалкогольна жирова хвороба печінки, diabetes mellitus type two, DPP-4 inhibitor, probiotic

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=scientific_p::e3635fc9bfeebef71c077eb0e525b0d0
http://family-medicine.com.ua/article/view/225464

المؤلفون: Бабенко, А. Ю., Лихоносов, М. П., Лихоносова, А. П.

المصدر: Clinical Endocrinology and Endocrine Surgery; No. 2(47) (2014); 3-11 ; Clinical Endocrinology and Endocrine Surgery; № 2(47) (2014); 3-11 ; 2519-2582 ; 1818-1384

مصطلحات موضوعية: glycemia variability, continuous glucose monitoring, incretins, GLP-1 analogues/mimetics, DPP-4 inhibitors, cardiovascular complications, diabetes mellitus, вариабельность гликемии, непрерывный мониторинг глюкозы, инкретины, аналоги/миметики ГПП-1, ингибиторы ДПП-4, сердечно-сосудистые осложнения сахарного диабета

وصف الملف: application/pdf

Relation: http://jcees.endocenter.kiev.ua/article/view/75427/70962; http://jcees.endocenter.kiev.ua/article/view/75427

الاتاحة: http://jcees.endocenter.kiev.ua/article/view/75427
https://doi.org/10.24026/1818-1384.2(47).2014.75427

المؤلفون: Бабенко, Алина, Красильникова, Елена, Лихоносов, Николай, Лихоносова, Анна, Гринева, Елена

مصطلحات موضوعية: НЕПРЕРЫВНОЕ МОНИТОРИРОВАНИЕ ГЛЮКОЗЫ, ВАРИАБЕЛЬНОСТЬ ГЛИКЕМИИ, ИНКРЕТИНЫ, АНАЛОГИ/МИМЕТИКИ ГПП-1, ИНГИБИТОРЫ ДПП-4, GLP-1 ANALOGUES/MIMETICS

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/vliyanie-razlichnyh-grupp-saharosnizhayuschih-preparatov-na-variabelnost-glikemii-u-bolnyh-saharnym-diabetom-2-tipa
http://cyberleninka.ru/article_covers/15702791.png

المؤلفون: Бирюкова, Е.

مصطلحات موضوعية: САХАРНЫЙ ДИАБЕТ 2 ТИПА, ИНГИБИТОРЫ ДПП-4, ИНКРЕТИНЫ, ВИЛДАГЛИПТИН

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/vildagliptin-v-klinicheskoy-praktike-analiz-sravnitelnyh-issledovaniy-lekarstvennyh-sredstv-s-inkretinovoy-aktivnostyu
http://cyberleninka.ru/article_covers/15544689.png

المؤلفون: Недосугова, Людмила, Петунина, Нина, Галстян, Карина

مصطلحات موضوعية: САХАРНЫЙ ДИАБЕТ, ГЛИКИРОВАННЫЙ ГЕМОГЛОБИН, ИНГИБИТОРЫ ДПП-4, ГОСОГЛИПТИН, ВИЛДАГЛИПТИН

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/novyy-ingibitor-dipeptidil-peptidazy-4-gosogliptin-pervyy-opyt-izucheniya-effektivnosti-i-bezopasnosti-pri-saharnom-diabete-2-tipa-v
http://cyberleninka.ru/article_covers/15702792.png

المؤلفون: Петунина, Н., Терехова, А.

مصطلحات موضوعية: АЛОГЛИПТИН, ИНГИБИТОРЫ ДПП-4, ЭФФЕКТИВНОСТЬ, БЕЗОПАСНОСТЬ, СЕРДЕЧНО-СОСУДИСТЫЙ РИСК, ГИПОГЛИКЕМИЯ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/alogliptin-novyy-predstavitel-klassa-ingibitorov-dpp-4
http://cyberleninka.ru/article_covers/15719337.png

المؤلفون: Сунцов, Юрий

مصطلحات موضوعية: САХАРНЫЙ ДИАБЕТ 2 ТИПА, АНАЛОГИ ЧЕЛОВЕЧЕСКОГО ИНСУЛИНА, ИНГИБИТОРЫ ДПП-4, АГОНИСТЫ ГПП-1

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/sovremennye-saharosnizhayuschie-preparaty-ispolzuemye-v-rossii-pri-lechenii-saharnogo-diabeta-2-tipa
http://cyberleninka.ru/article_covers/14026242.png